Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vir Biotechnology, Inc. - Common Stock
(NQ:
VIR
)
11.40
+0.22 (+1.97%)
Delayed Quote
Updated: 2:45 PM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vir Biotechnology, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
August 25, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir (VIR) Q2 Revenue Drops 61%
↗
August 07, 2025
Via
The Motley Fool
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 06, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
August 06, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Earnings Scheduled For August 6, 2025
↗
August 06, 2025
Via
Benzinga
Earnings Scheduled For May 7, 2025
↗
May 07, 2025
Via
Benzinga
Earnings Outlook For Vir Biotechnology
↗
May 06, 2025
Via
Benzinga
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
July 31, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
July 24, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
5 Analysts Have This To Say About Vir Biotechnology
↗
April 17, 2025
Via
Benzinga
7 Analysts Have This To Say About Vir Biotechnology
↗
February 28, 2025
Via
Benzinga
Earnings Scheduled For February 26, 2025
↗
February 26, 2025
Via
Benzinga
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025
July 22, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
July 11, 2025
Via
Benzinga
Where Vir Biotechnology Stands With Analysts
↗
July 11, 2025
Via
Benzinga
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
May 28, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
↗
May 22, 2025
Via
Benzinga
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
May 20, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
May 12, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
↗
May 12, 2025
Via
Benzinga
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
May 09, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 07, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025
April 30, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
April 24, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
March 13, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
February 26, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
February 19, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
February 12, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
↗
January 10, 2025
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
January 08, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
